On the risk of delisting of ordinary shares of Moleculin Biotech, Inc. (MBRX)

The International Trading System Limited (ITS) hereby informs on the delisting risk of ordinary shares of Moleculin Biotech, Inc. (ISIN US60855D3098) from The NASDAQ Stock Market LLC (Nasdaq).  

Information on delisting risk of ordinary shares by Nasdaq

On November 21, 2025 Moleculin Biotech, Inc. (the Company) submitted Current report Form 8-K to The United States Securities and Exchange Commission (SEC). According to the report, on November 20, 2025 the Company received a delisting determination from Nasdaq after not regaining compliance with the minimum $2.5 million stockholders’ equity requirement under Listing Rule 5550(b)(1) by the extended deadline of November 19, 2025. Unless the Company requests a hearing panel appeal of the delist determination by November 28, 2025, its securities would be delisted on December 2, 2025.

The Company intends to appeal the decision to a Nasdaq Hearings Panel.

Information regarding possible actions to be taken by ITS Ltd.

If Nasdaq suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognized Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.